Accumulation of Treatment and Clinical Data and Evidence Generation
First written in FY2019. 3 of 7 entries say "Restated". Latest entry: 2026-08-12.
7 other companies' latest entry also says "Advanced".
- 2026-08-12AdvancedMonthly
「We have handled more than 130,000 outsourced cell and other processing cases at an authorized facility for the manufacture of specified processed cells (facility number: FA3240004) under the Act on the Safety of Regenerative Medicine,」
The cumulative record of outsourced cell and other processing increased from the previously stated figure of "more than 90,000 cases" to "more than 130,000 cases." - FY2025AdvancedAnnual report
「The Group has accumulated more than 90,000 contract processing cases to date, but will continue to regard further accumulation of data and establishment of evidence as important management priorities, while also strengthening and improving the relevant methods.」
The contract processing track record increased from more than 80,000 cases in the previous disclosure to more than 90,000 cases, indicating an expanded foundation for accumulating data and establishing evidence. - FY2023AdvancedAnnual report
「The company has accumulated more than 80,000 contract processing cases to date, but will continue to regard further accumulation of data and establishment of evidence as important management priorities, while also strengthening and improving the relevant methods.」
The company specifically disclosed for the first time that its contract processing track record had exceeded 80,000 cases, expanding the foundation for accumulating treatment and clinical data and establishing evidence. - FY2022RestatedAnnual report
「We recognize that accumulating performance data on treatments, clinical care and other activities through contract processing results and collaboration with medical institutions and others, and establishing evidence, are essential for presenting findings at academic conferences and seminars, promoting collaboration with academia, physicians and others, and laying the groundwork for entering new business areas.」
The company continues to pursue a policy of using treatment and clinical data and evidence as the foundation for academic outreach, collaboration and new businesses. - FY2021RestatedAnnual report
「We recognize the accumulation of such data and establishment of evidence as important management priorities, and will also strengthen and improve the methods used to achieve them.」
The company continues to regard the accumulation of treatment and clinical data and the establishment of evidence as important priorities, and maintains a policy of strengthening and improving the relevant methods. - FY2020RestatedAnnual report
「We recognize the accumulation of such data and establishment of evidence as important management priorities, and will also strengthen and improve the methods used to achieve them.」
The company continues to regard the accumulation of treatment and clinical data and the establishment of evidence as important priorities, and maintains a policy of strengthening and improving the relevant methods. - FY2019First statedAnnual report
「We recognize that accumulating performance data on treatments, clinical care and other activities and establishing evidence are essential for presenting findings at academic conferences and seminars, promoting collaboration with academia, physicians and others, and laying the groundwork for entering new business areas.」
The company positions data and evidence as the foundation for academic outreach, collaboration and new businesses.